{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:28:27Z","timestamp":1785306507094,"version":"3.55.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.007","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:29:28Z","timestamp":1663118968000},"page":"657-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Inconvenient Truth of Primary Biliary Cholangitis\/Autoimmune Hepatitis Overlap Syndrome"],"prefix":"10.1016","volume":"26","author":[{"given":"Nasir","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cld.2022.06.007_bib1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","article-title":"Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome","volume":"8","author":"Kuiper","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.cld.2022.06.007_bib6","first-page":"739A","article-title":"Characterising normal patterns of alanine aminotransferase elevations in ursodeoxycholic acid-treated patients with primary biliary cholangitis","volume":"72","author":"Sioufi","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2022.06.007_bib8","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2022.06.007_bib9","first-page":"A10","article-title":"OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience","volume":"70","author":"Abbas","year":"2021","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.cld.2022.06.007_bib10","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2013.12.010","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics","volume":"12","author":"Levy","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7\u20138","key":"10.1016\/j.cld.2022.06.007_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cca.2010.12.019","article-title":"Disease-specific autoantibodies in primary biliary cirrhosis","volume":"412","author":"Bogdanos","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis","volume":"48","author":"O'Brien","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cgh.2012.02.010","article-title":"Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis","volume":"10","author":"Dinani","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2022.06.007_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1478-3231.2007.01538.x","article-title":"Development of autoimmune hepatitis in primary biliary cirrhosis","volume":"27","author":"Gossard","year":"2007","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A\u00a0placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/jhep.2002.30902","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid","volume":"35","author":"Joshi","year":"2002","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.cld.2022.06.007_bib20","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.3748\/wjg.v20.i13.3597","article-title":"Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis","volume":"20","author":"Kobayashi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2022.06.007_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","article-title":"Autoimmune hepatitis with incidental histologic features of bile duct injury","volume":"34","author":"Czaja","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2018.03.008","article-title":"Liver biopsy in primary biliary cholangitis: indications and interpretation","volume":"22","author":"Tan","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cgh.2019.11.024","article-title":"IgG:IgM ratios of liver plasma cells reveal similar phenotypes of primary biliary cholangitis with and without features of autoimmune hepatitis","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","article-title":"Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals","volume":"29","author":"Lohse","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.007_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.03.040","article-title":"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis","author":"Boettler","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2022.06.007_bib27","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep4.1582","article-title":"Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype","volume":"4","author":"Lammert","year":"2020","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.007_bib29","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"issue":"19","key":"10.1016\/j.cld.2022.06.007_bib30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1440-1746.1994.tb01237.x","article-title":"A\u00a0two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis","volume":"9","author":"Turner","year":"1994","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib35","first-page":"759","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2022.06.007_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.1998.00395.x","article-title":"A\u00a0randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10\u00a0mg\/kg or 20\u00a0mg\/kg. Dutch Multicentre PBC Study Group","volume":"12","author":"Van Hoogstraten","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"9184","key":"10.1016\/j.cld.2022.06.007_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib38","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2022.06.007_bib39","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2022.06.007_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.06.007_bib42","first-page":"5407","article-title":"Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis","volume":"9","author":"Yin","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","article-title":"Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA","volume":"50","author":"Tanaka","year":"2015","journal-title":"J\u00a0Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A\u00a0prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.cld.2022.06.007_bib47","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib51","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.007_bib53","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2022.06.007_bib54","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"10.1016\/j.cld.2022.06.007_bib55","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.007_bib57","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib59","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib60","first-page":"148","article-title":"A\u00a0meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations","volume":"10","author":"Zhang","year":"2015","journal-title":"Prz Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouill\u00e8res","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.007_bib62","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","article-title":"Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis","volume":"41","author":"Wang","year":"2013","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib64","article-title":"Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis","volume":"9","author":"Freedman","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.cld.2022.06.007_bib65","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3350\/cmh.2015.21.2.150","article-title":"Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes","volume":"21","author":"Park","year":"2015","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.007_bib67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.gastrohep.2018.05.019","article-title":"Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital","volume":"41","author":"Mart\u00ednez Casas","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.007_bib68","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib69","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MEG.0000000000000075","article-title":"Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis","volume":"26","author":"Efe","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12936","article-title":"Histologic surveillance after liver transplantation due to autoimmune hepatitis","volume":"31","author":"Puustinen","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cld.2022.06.007_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.01.022","article-title":"Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation","author":"Montano-Loza","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib72","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2022.06.007_bib73","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, sex, and inflammatory bowel disease phenotype Associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.007_bib75","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.007_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15241","article-title":"Treatment and outcome of autoimmune hepatitis (AIH): audit of 28\u00a0UK centres","author":"Gordon","year":"2022","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/flgastro-2020-101661","article-title":"Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH)","volume":"13","author":"Gordon","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14309\/ajg.0000000000001525","article-title":"Increased cancer risk in autoimmune hepatitis: a Danish nationwide cohort study","volume":"117","author":"Jensen","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.007_bib79","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/liv.14480","article-title":"Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study","volume":"40","author":"Gr\u00f8nbaek","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib81","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.007_bib82","doi-asserted-by":"crossref","first-page":"100321","DOI":"10.1016\/j.jhepr.2021.100321","article-title":"Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis","volume":"3","author":"Laschtowitz","year":"2021","journal-title":"JHEP Rep"},{"issue":"47","key":"10.1016\/j.cld.2022.06.007_bib83","first-page":"1195","article-title":"Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"49","author":"G\u00fcnsar","year":"2002","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5387\/fms.52.71","article-title":"Clinicolaboratory characteristics of Japanese patients with primary biliary cirrhosis-autoimmune hepatitis overlap","volume":"52","author":"Saito","year":"2006","journal-title":"Fukushima J Med Sci"},{"issue":"3","key":"10.1016\/j.cld.2022.06.007_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00029330-200602010-00013","article-title":"Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study","volume":"119","author":"Wu","year":"2006","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease","volume":"31","author":"Heurgu\u00e9","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1440-1746.2009.06018.x","article-title":"Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes","volume":"25","author":"Yokokawa","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.007_bib88","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1872-034X.2011.00844.x","article-title":"Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan","volume":"41","author":"Tanaka","year":"2011","journal-title":"Hepatol Res"},{"issue":"12","key":"10.1016\/j.cld.2022.06.007_bib89","first-page":"660","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients","volume":"15","author":"Liu","year":"2014","journal-title":"J\u00a0Dig Dis"},{"issue":"9","key":"10.1016\/j.cld.2022.06.007_bib90","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hepr.12210","article-title":"Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: importance of corticosteroid therapy","volume":"44","author":"Yoshioka","year":"2014","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.cld.2022.06.007_bib91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cld.2022.06.007_bib92","doi-asserted-by":"crossref","first-page":"1965492","DOI":"10.1155\/2018\/1965492","article-title":"Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: a real-world study","volume":"2018","author":"Fan","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.007_bib93","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser","year":"2010","journal-title":"Am J Gastroenterol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:00Z","timestamp":1761069540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000459"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Inconvenient Truth of Primary Biliary Cholangitis\/Autoimmune Hepatitis Overlap Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}